Session Information

  • WCLC 2021

    2021 World Conference on Lung Cancer

    Conference Program for 2021 the World Conference on Lung Cancer

    Presentation Date(s):  
    • September 8 - 14, 2021
    • Total Presentations: 1107

    All times listed are in Mountain Time MDT (UTC-6:00)

    PL - Plenary
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    WS - Workshops
    IS - Industry Symposium
    MTE - Meet the Expert
    BEDG - Brain Exchange Discussion Groups

Filter Results:

Show Only CME Accredited Sessions

  • +

    P50 - Novel Therapeutics and Targeted Therapies - EGFR Minor

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      P50.01 - RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19-del Variants

      00:00 - 00:00  |  Presenter: Kazumi Nishino

      • Abstract

      Loading...

    • +

      P50.03 - A Real-World Cohort Study of EGFR TKIs in Patients with NSCLC with Uncommon EGFR mutations (UpSwinG)

      00:00 - 00:00  |  Presenter: Satoru Miura

      • Abstract

      Loading...

    • +

      P50.04 - Amivantamab in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

      00:00 - 00:00  |  Presenter: Misako Nagasaka

      • Abstract

      Loading...

    • +

      P50.05 - Natural History and Real-World Treatment Outcomes for NSCLC Patients with EGFR Exon 20 Insertion Mutation: An IASLC- ASCO CancerLinQ Study

      00:00 - 00:00  |  Presenter: Madhusmita Behera

      • Abstract

      Loading...

    • +

      P50.06 - First-Line Therapy in NSCLC harbouring EGFR or HER2 Exon 20 Insertion Mutation. Hunting for the Best Candidate

      00:00 - 00:00  |  Presenter: Sara Manglaviti

      • Abstract

      Loading...

    • +

      P50.07 - Afatinib Treatment Response in Advanced Lung Adenocarcinomas Harboring Uncommon Mutations in Chinese Population

      00:00 - 00:00  |  Presenter: Teng Li

      • Abstract

      Loading...

    • +

      P50.08 - Targeting HER2 or EGFR Exon 20 Insertion Mutation in Lung Cancer - A Case Series from India  

      00:00 - 00:00  |  Presenter: Vivek Joseph Varughese

      • Abstract

      Loading...

    • +

      P50.09 - Characteristics and Clinical Outcomes of HER2 Mutated Non-small Cell Lung Cancer Patients Detected by NGS in Routine Clinical Practice

      00:00 - 00:00  |  Presenter: Yejeong Han

      • Abstract

      Loading...

  • +

    P51 - Novel Therapeutics and Targeted Therapies - EGFR Resistance

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      P51.01 - Tepotinib Plus an EGFR TKI in Patients with EGFR-mutant NSCLC and Resistance to EGFR TKIs Due to MET Amplification (METamp)

      00:00 - 00:00  |  Presenter: Chong Kin Liam

      • Abstract

      Loading...

    • +

      P51.02 - Stacking on the Targets: Secondary Resistant, Potential Targetable Genetic Alterations in Patients With Epidermal Growth Factor Receptor NSCLC

      00:00 - 00:00  |  Presenter: Nagashree Seetharamu

      • Abstract

      Loading...

    • +

      P51.03 - Oritinib (SH-1028), a Third-generation EGFR-TKI in Advanced NSCLC Patients with Positive EGFR T790M: Results of a Single-arm Phase Ib Trial

      00:00 - 00:00  |  Presenter: Caicun Zhou

      • Abstract

      Loading...

    • +

      P51.04 - Pattern of Disease Progression on Osimertinib and Subsequent Treatment in Patients with EGFR- Mutated Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Hyesook Kim

      • Abstract

      Loading...

    • +

      P51.05 - Sequential Afatinib and Osimertinib in Patients With Advanced EGFRm+ NSCLC and Acquired T790M: The Real-World UpSwinG study

      00:00 - 00:00  |  Presenter: Sanjay Popat

      • Abstract

      Loading...

    • +

      P51.06 - Outcomes of First-Line TKI Treated Advanced NSCLC with Distinct Types of EGFR Mutations: Brain Metastasis and de Novo T790M

      00:00 - 00:00  |  Presenter: Ya Zeng

      • Abstract

      Loading...

    • +

      P51.07 - Small Cell Transformation of Non Small Cell Lung Carcinoma: Tissue Biopsy Is Here to Stay!

      00:00 - 00:00  |  Presenter: Mansi Sharma

      • Abstract

      Loading...

  • +

    P52 - Novel Therapeutics and Targeted Therapies - KRAS

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      P52.01 - Understanding Treatment Preferences of Patients With KRAS p.G12C[LC1] [MK2] – Mutated Advanced Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Kelley Myers

      • Abstract

      Loading...

    • +

      P52.02 - High SHP2 Expression Determines the Efficacy of PD-1/PD-L1 Inhibitors in Advanced KRAS Mutant Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Hui-Bo Feng

      • Abstract

      Loading...

    • +

      P52.03 - Efficacy of Sotorasib in KRAS p.G12C-Mutated NSCLC with Stable Brain Metastases: A Post-Hoc Analysis of CodeBreaK 100

      00:00 - 00:00  |  Presenter: Suresh Ramalingam

      • Abstract

      Loading...

    • +

      P52.04 - Histone Deacetylase 6 Inhibition Reveals Metabolic Vulnerabilities in KRAS Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Catriona M Dowling

      • Abstract

      Loading...

    • +

      P52.05 - Dual RAF/MEK Inhibitor VS-6766 for Treatment of KRAS Mutant NSCLC: Novel Combinations Targeting G12C or G12V Variants

      00:00 - 00:00  |  Presenter: Jonathan A Pachter

      • Abstract

      Loading...

  • +

    P53 - Novel Therapeutics and Targeted Therapies - Others

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      P53.01 - Clinical Application of NGS Technology. Therapeutic Possibilities and Future Perspectives

      00:00 - 00:00  |  Presenter: Silvia Sequero-Lopez

      • Abstract

      Loading...

    • +

      P53.02 - Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase (TRK) Fusion-Positive Lung Cancer

      00:00 - 00:00  |  Presenter: Alexander Drilon

      • Abstract

      Loading...

    • +

      P53.03 - The Characteristics of FGFR Genetic Aberrations in Chinese Lung Cancer Patients

      00:00 - 00:00  |  Presenter: Xiuqin Zhang

      • Abstract

      Loading...

    • +

      P53.04 - Local Therapies vs. Specific TKIs as the Initial Treatment for Oligo-Recurrent Lung Adenocarcinoma With Driver Mutations

      00:00 - 00:00  |  Presenter: Yosuke Matsuura

      • Abstract

      Loading...

    • +

      P53.05 - Inhibition of Tumor Cell Intrinsic Complement Regulatory Proteins Leads to Decreased Tumor Growth in a Mouse Model of NSCLC

      00:00 - 00:00  |  Presenter: Emily K Kleczko

      • Abstract

      Loading...

    • +

      P53.06 - A Multi-Phase Quality Initiative to Improve Processes of Care for Non-small Cell Lung Cancer (NSCLC) in US Community Cancer Centers

      00:00 - 00:00  |  Presenter: Matthew Smeltzer

      • Abstract

      Loading...

    • +

      P53.07 - Clinical and Genomic Insights Into of Chinese Lung Cancer Patients with HER2 Amplification

      00:00 - 00:00  |  Presenter: Chengzhi Zhou

      • Abstract

      Loading...

    • +

      P53.08 - Concomitant Fibrates and Immunotherapy in Non-Small Cell Lung Cancer Patients in the Veterans Health Administration

      00:00 - 00:00  |  Presenter: William A Stokes

      • Abstract

      Loading...

  • +

    P54 - Palliative and Supportive Care

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Palliative and Supportive Care
    • +

      P54.01 - Analysis of the Support Needs of Lung Cancer Patients

      00:00 - 00:00  |  Presenter: Christie Lagogianni

      • Abstract

      Loading...

    • +

      P54.02 - Palliative Treatment of Tumor Stenoses of the Trachea and Bronchi

      00:00 - 00:00  |  Presenter: Vladyslav Severgin

      • Abstract

      Loading...

    • +

      P54.03 - Bilateral Indwelling Pleural Catheters

      00:00 - 00:00  |  Presenter: Avinash Aujayeb

      • Abstract

      Loading...

    • +

      P54.04 - Detecting Elevated Risk of Diminished Quality of Life Among Lung Cancer Patients by Using Wearable Devices

      00:00 - 00:00  |  Presenter: Maria Torrente

      • Abstract

      Loading...

    • +

      P54.05 - Stereotactic Radiotherapy for Brain Metastases in Patients With Lung Cancer: Cyberknife Experience

      00:00 - 00:00  |  Presenter: Süreyya Sarıhan

      • Abstract

      Loading...

    • +

      P54.06 - The FITNESS Study: Geriatric Assessment, Treatment Toxicity, and Biospecimen Collection Among Older Adults With Lung Cancer

      00:00 - 00:00  |  Presenter: Madison Grogan

      • Abstract

      Loading...

  • +

    P55 - Patient Advocacy

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Patient Advocacy
    • +

      P55.01 - Standard of Care Disparity in a Global Cancer Support Group: Examining an Advocate Survey to Inspire Change.

      00:00 - 00:00  |  Presenter: Jamie Gibbard

      • Abstract

      Loading...

    • +

      P55.02 - Robotic Surgery in Canada: Are Patients Willing to Pay Out-of-Pocket?

      00:00 - 00:00  |  Presenter: Yogita S. Patel

      • Abstract

      Loading...

    • +

      P55.03 - Results of The First Survey Using EORTC QLQ INFO25 on Information Acquisition and Satisfaction of Lung Cancer Patients in Japan

      00:00 - 00:00  |  Presenter: Takayuki Takahama

      • Abstract

      Loading...

  • +

    P56 - Predictive Tumor Based Assays/ Biomarkers/ Pathology - Histopathology

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Predictive Tumor Based Assays/ Biomarkers/ Pathology
    • +

      P56.01 - Semiquantitative Assessment of Tumor Spread Through Air Spaces in a Historic Cohort of Lung Adenocarcinomas Following Open Surgical Resection

      00:00 - 00:00  |  Presenter: WEIWEI SHI

      • Abstract

      Loading...

    • +

      P56.02 - Novel Low Malignant Potential/Vascular Invasive (LMPVI) Grade is Superior to WHO 2015 and IASLC 2020 Adenocarcinoma Grade

      00:00 - 00:00  |  Presenter: Ilyas Yambayev

      • Abstract

      Loading...

    • +

      P56.03 - Prognostic Value of Tumor Spread Through Air Spaces in Patients With Lung Adenocarcinoma after Radical Surgery

      00:00 - 00:00  |  Presenter: Shiqi Chen

      • Abstract

      Loading...

    • +

      P56.04 - Pathological Features & Prognosis of NSCLC Patients With Enteric Adenocarcinomas Without Expression of TTF-1 and Napsin A

      00:00 - 00:00  |  Presenter: Daniel Christian Christoph

      • Abstract

      Loading...

    • +

      P56.05 - Detection Rate and Prognosis of Nodal-Micro Metastasis by IHC in pN0 Resectable Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenter: sophon - Siwachat

      • Abstract

      Loading...

    • +

      P56.06 - Clinical Significance and Potential Function of S100A10 in Lung Adenocarcinoma

      00:00 - 00:00  |  Presenter: Jiyan Dong

      • Abstract

      Loading...

  • +

    P57 - Predictive Tumor Based Assays/ Biomarkers/ Pathology - ICI Biomarkers

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Predictive Tumor Based Assays/ Biomarkers/ Pathology
    • +

      P57.01 - Immunotherapy Fits Everyone? Prognostic Markers for Immune-checkpoint-Inhibitor (ICI) in Non-small Cell Lung Cancer (NSCLC)

      00:00 - 00:00  |  Presenter: Susana Baptista de Almeida

      • Abstract

      Loading...

    • +

      P57.02 - Integration of Systemic / Tumor PD-L1 as a Predictive Biomarker of Clinical Outcome in Advanced NSCLC Patients Treated With Anti-PD-(L)1 Agents

      00:00 - 00:00  |  Presenter: Margarita Majem

      • Abstract

      Loading...

    • +

      P57.03 - Cellular Engagement and Interaction in the Tumor Microenvironment (TME) Predicts Response to ICI in Metastatic NSCLC

      00:00 - 00:00  |  Presenter: Angel Qin

      • Abstract

      Loading...

    • +

      P57.04 - Predicting Treatment Response to 1st- line Pembrolizumab in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients with High PDL1 Expression

      00:00 - 00:00  |  Presenter: Ian K. N. Janzen

      • Abstract

      Loading...

    • +

      P57.05 - Low Variant Allele Frequency of TP53 as a Biomarker for PD-1/PD-L1 Inhibitors in Lung Adenocarcinoma

      00:00 - 00:00  |  Presenter: Shouzheng Wang

      • Abstract

      Loading...

    • +

      P57.06 - EGFR Mutational Status and PD-L1 in Early-Stage Brazilian Non-Small-Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Leticia Ferro Leal

      • Abstract

      Loading...

    • +

      P57.07 - The Scottish Immunotherapy Prognostic Score (SIPS) Predicts Response to First-Line Pembrolizumab for Metastatic Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Mark Stares

      • Abstract

      Loading...

    • +

      P57.08 - High Performance Radiomic Classifier to Predict the Response to Immunotherapy in Advanced NSCLC

      00:00 - 00:00  |  Presenter: Giulia Mazzaschi

      • Abstract

      Loading...

    • +

      P57.09 - Common Oncogenic Driver Mutations and PD-L1 Expression in Non-Small Cell Lung Cancer of Smokers and Never Smokers

      00:00 - 00:00  |  Presenter: Chong Kin Liam

      • Abstract

      Loading...

    • +

      P57.10 - Clinicopathological Analysis of Anti-Tumor Immunology-Related Factors After Chemoradiotherapy for Lung Cancer

      00:00 - 00:00  |  Presenter: Misa Noguchi

      • Abstract

      Loading...

    • +

      P57.11 - The Role of Serum Proteomic Signature in Predicting Survival by PD-L1 Status in Patients With Non-Small Cell Lung Cancer Receiving Immunotherapy

      00:00 - 00:00  |  Presenter: Leeseul Kim

      • Abstract

      Loading...

    • +

      P57.12 - Clinical and Molecular Features of Chinese Lung Cancer Patients With Germline Mismatch Repair Gene Mutations

      00:00 - 00:00  |  Presenter: Jing Bai

      • Abstract

      Loading...

    • +

      P57.13 - Correlation of TP53/KMT2C co-mutation and Tumor Microenvironment in Lung Cancer

      00:00 - 00:00  |  Presenter: Xuhui Zhang

      • Abstract

      Loading...

    • +

      P57.14 - LRMP Associates With Immune Infiltrates and Acts as a Prognostic Biomarker in Lung Adenocarcinoma

      00:00 - 00:00  |  Presenter: xin jin

      • Abstract

      Loading...

    • +

      P57.15 - Safety and Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Low Creatinine Clearance Rate

      00:00 - 00:00  |  Presenter: Jia-Yi Deng

      • Abstract

      Loading...

    • +

      P57.16 - Inflammatory Markers as Predictors of Treatment Response and Survival in Patients With Non-Small Cell Lung Cancer Treated with PD-1 Inhibitors

      00:00 - 00:00  |  Presenter: Ioannis Gkiozos

      • Abstract

      Loading...

  • +

    P58 - Predictive Tumor Based Assays/ Biomarkers/ Pathology - Predictive Biomarkers/ Pathology

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Predictive Tumor Based Assays/ Biomarkers/ Pathology
    • +

      P58.01 - Dysbiosis of Fecal Microbiome in Advanced Non-Small-Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Xueqin Chen

      • Abstract

      Loading...

  • +

    P59 - Predictive Tumor Based Assays/ Biomarkers/ Pathology - Targeted Therapies Biomarkers

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Predictive Tumor Based Assays/ Biomarkers/ Pathology
    • +

      P59.01 - Clinical Characteristics of Patients With MET Amplification-Positive NSCLC After EGFR-TKI Therapy

      00:00 - 00:00  |  Presenter: Ji Hyun Lee

      • Abstract

      Loading...

    • +

      P59.02 - Profile of Next-Generation Sequencing (NGS) on MET exon 14 Skipping Mutation and MET Amplification in Lung Cancer: A Calibration Project in China

      00:00 - 00:00  |  Presenter: Wei Wu

      • Abstract

      Loading...

    • +

      P59.03 - Comparison of Two RNA-Based Platforms for Detection of Fusions and Met Splicing Variant in Non Small Cell Lung Cancer Samples  

      00:00 - 00:00  |  Presenter: Clara Mayo-de-las-Casas

      • Abstract

      Loading...

    • +

      P59.04 - Molecular Characterization of Unactionable EGFR Mutation in Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenter: HuiTa Wu

      • Abstract

      Loading...

    • +

      P59.05 - Integration of Molecular Cancer Classification and NGS to Identify Metastatic Cancer Patients Eligible For Lung Cancer Directed Therapy

      00:00 - 00:00  |  Presenter: Kaushal Parikh

      • Abstract

      Loading...

    • +

      P59.06 - Prognostic Nutritional Index in Real-World Patients Receiving Systemic Therapy for Driver Mutation-Positive Metastatic NSCLC

      00:00 - 00:00

      • Abstract

      Loading...

    • +

      P59.07 - Mutation Profile of BRAF in Chinese Non-Small Cell Lung Cancer Patients

      00:00 - 00:00  |  Presenter: Xinghao Ai

      • Abstract

      Loading...

    • +

      P59.08 - Identifying the Origin of Lung-Specific Cancer of Unknown Primary Based on Comprehensive Genomic Profiling Optimized With DNA Methylation

      00:00 - 00:00  |  Presenter: Yun Fan

      • Abstract

      Loading...

    • +

      P59.09 - Landscape of Targetable Genomic Alterations in Hispanic/Latinx Patients With Non-Small Cell Lung Cancers

      00:00 - 00:00  |  Presenter: Ana Isabel Velazquez

      • Abstract

      Loading...

    • +

      P59.10 - A Sneak Peak in the Future World of EGFR Mutations: ML Based PFS Differences Between Del 19 and L858R

      00:00 - 00:00  |  Presenter: Ullas Batra

      • Abstract

      Loading...

    • +

      P59.11 - Real-World Data of NGS Diagnostic Biomarker Testing for Lung Cancer Patients in Japan

      00:00 - 00:00  |  Presenter: Toshiaki Takahashi

      • Abstract

      Loading...

    • +

      P59.12 - KRAS Mutation Subtypes in Non-Small Cell Lung Cancer and Clinical Outcomes: A Single Centre Experience

      00:00 - 00:00  |  Presenter: Alexander Patrick Davis

      • Abstract

      Loading...

    • +

      P59.13 - The Prediction Performance of TP53 / RB1 Co-Mutation on Small-Cell Lung Cancer Transformation in Patients With Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Zaiwen Fan

      • Abstract

      Loading...

    • +

      P59.14 - Concordance and Performance of ddPCR Compared to NGS for The Detection of KRAS G12C Mutation 

      00:00 - 00:00  |  Presenter: Andres Felipe Cardona Zorrilla

      • Abstract

      Loading...

    • +

      P59.15 - Is CD73 Expression a Druggable Mechanism of Resistance in EGFR-TKI-Treated EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)?

      00:00 - 00:00  |  Presenter: Inger Johanne Eide

      • Abstract

      Loading...

    • +

      P59.16 - Characterizing the Tumour-Immune Microenvironment in EGFR Mutant NSCLC

      00:00 - 00:00  |  Presenter: Ken O'Byrne

      • Abstract

      Loading...

    • +

      P59.17 - EGFR Mutation Status, Liver Metastasis, and Overall Survival in Advanced Lung Adenocarcinoma Patients

      00:00 - 00:00  |  Presenter: Preet Walia

      • Abstract

      Loading...

    • +

      P59.18 - Evaluation of ROS1 Expression in a Large Cohort of Early Stage Lung Cancer

      00:00 - 00:00  |  Presenter: Anne Pernille Harlem Dyrbekk

      • Abstract

      Loading...

    • +

      P59.19 - MET Alterations and Co-Drivers With Poor Prognosis in Patients With Metastatic Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Maritza Ramos-Ramirez

      • Abstract

      Loading...

    • +

      P59.20 - Natural History of KRAS Mutant Non-Small-Cell Lung Cancer in the Immunotherapy Era: A Single-Centre Retrospective Study

      00:00 - 00:00  |  Presenter: Paolo Bironzo

      • Abstract

      Loading...

    • +

      P59.21 - Impact of Reflex Testing on Pathology Based Molecular Testing in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

      00:00 - 00:00  |  Presenter: Melina E. Marmarelis

      • Abstract

      Loading...

    • +

      P59.22 - Biomarker Testing for Advanced Lung Cancer by Next-Generation Sequencing in Real World Practice

      00:00 - 00:00  |  Presenter: Jose Nicolas Minatta

      • Abstract

      Loading...

    • +

      P59.23 - Biomarker Testing for Non-Small Cell Lung Cancer at a Tertiary Referral Hospital in Ireland: Challenges and Opportunities

      00:00 - 00:00  |  Presenter: Philip Bredin

      • Abstract

      Loading...

    • +

      P59.24 - Genomic Abnormalities in Malignant Pleural Effusion of Lung Cancer Patients Detected by Multiplex Ligation-Dependent Probe Amplification 

      00:00 - 00:00  |  Presenter: Caroline Silvério Faria

      • Abstract

      Loading...

    • +

      P59.25 - Prognostic and Treatment Characteristics of Metastatic KRAS G12C Mutant NSCLC

      00:00 - 00:00  |  Presenter: Anifat Elegbede

      • Abstract

      Loading...

    • +

      P59.26 - Comparison of RT-PCR, NGS and FISH/IHC Methods in Detection of Gene Fusions

      00:00 - 00:00  |  Presenter: Yue Pu

      • Abstract

      Loading...

    • +

      P59.27 - Complementary Utility of Combined ALK/ROS1 FISH with Immunohistochemistry for ALK/ROS1 Rearrangement Testing in Lung Cancer

      00:00 - 00:00  |  Presenter: Aruna Nambirajan

      • Abstract

      Loading...

    • +

      P59.28 - Protocol Adaptation for gDNA Extraction of FFPE Samples of Lung Adenocarcinoma Tissue and Related Mediastinal Lymph Nodes

      00:00 - 00:00  |  Presenter: Caroline Silvério Faria

      • Abstract

      Loading...

    • +

      P59.29 - Frequency of PIK3CA Mutations and Therapeutic Outcomes in NSCLC

      00:00 - 00:00  |  Presenter: Guillermo Martos

      • Abstract

      Loading...

    • +

      P59.30 - Genomic Landscape of Lung Cancer in the Young

      00:00 - 00:00  |  Presenter: Rossana Ruiz

      • Abstract

      Loading...

    • +

      P59.31 - A High Number of Co-Current Genetic Alterations Is Associated With Poor Survival in EGFR Mutated Metastatic NSCLC Patients

      00:00 - 00:00  |  Presenter: David Heredia

      • Abstract

      Loading...

    • +

      P59.32 - Physician Attitudes Toward Genetic Testing and Targeted Therapy for Advanced NSCLC Patients in China: A Nationwide Survey

      00:00 - 00:00  |  Presenter: Xiao Meng

      • Abstract

      Loading...